Arabic Arabic English English French French German German
dark

FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease

Alkeus Pharmaceuticals, Inc., a private, late-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Health Volunteer Center Participates in Serving Pilgrims during this Year’s Hajj Season

Next Post

Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne

Related Posts
Total
0
Share